Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain

Pain

Volumn 156, Issue 10, 2015, Pages 2001-2012

  Porta, Carmen La ^a   Andreea Bura, S ^a,f   Llorente Onaindia, Jone ^b   Pastor, Antoni ^b,c   Navarrete, Francisco ^d   García Gutierrez, María Salud ^d   De La Torre, Rafael ^a,b,e   Manzanares, Jorge ^e   Monfort, Jordi ^b,c   Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e Instituto de Salud Carlos III   (Spain)

^f MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

2 Arachidonoylglycerol; Anandamide; Animal model; Anxiety; Cannabinoid receptor 1; Cannabinoid receptor 2

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; CORTICOTROPIN RELEASING FACTOR; ENZYME INHIBITOR; GLUCOCORTICOID RECEPTOR; GLYCERYL 2-ARACHIDONATE; IODOACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EMOTIONAL DISORDER; GENE EXPRESSION; GENE INACTIVATION; HUMAN; KNEE OSTEOARTHRITIS; MALE; MEMORY DISORDER; MOOD DISORDER; MOUSE; NONHUMAN; OSTEOARTHRITIS; PAIN; PERIPHERAL LYMPHOCYTE; PREFRONTAL CORTEX; PRIORITY JOURNAL; UPREGULATION; AGED; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COGNITION DISORDERS; COMPLICATION; DEFICIENCY; DRUG EFFECTS; FEMALE; GENETICS; KNOCKOUT MOUSE; MAZE TEST; METABOLISM; MIDDLE AGED; MOOD DISORDERS; PHYSIOLOGY;

AGED; ANIMALS; ARACHIDONIC ACIDS; COGNITION DISORDERS; CORTICOTROPIN-RELEASING HORMONE; ENDOCANNABINOIDS; ENZYME INHIBITORS; FEMALE; GLYCERIDES; HUMANS; IODOACETATES; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MOOD DISORDERS; OSTEOARTHRITIS; PREFRONTAL CORTEX; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, GLUCOCORTICOID;

EID: 84954568750     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000260     Document Type: Article

References (57)

1. Akirav I. The role of cannabinoids in modulating emotional and nonemotional memory processes in the hippocampus. Front Behav Neurosci 2011; 5:34.
2. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 2012; 13:93-110.
3. Axford J, ButtA, Heron C, HammondJ, Morgan J, AlaviA, Bolton J, Bland M. Prevalence of anxiety and depression in osteoarthritis: use of the Hospital Anxiety and Depression Scale as a screening tool. Clin Rheumatol 2010; 29: 1277-83.
4. Blackburn-Munro G, Blackburn-Munro RE. Chronic pain, chronic stress and depression: coincidence or consequence? J Neuroendocrinol 2001; 13:1009-23.
5. Burston JJ, Sagar DR, Shao P, Bai M, King E, Brailsford L, Turner JM, Hathway GJ, Bennett AJ, Walsh DA, Kendall DA, Lichtman A, Chapman V. Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 2013; 8:1-9.
6. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A. Differential role of anandamide and 2-Arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 2011; 70:479-86.
7. CastañéA, Célérier E, Martín M, Ledent C, Parmentier M, Maldonado R, Valverde O. Development and expression of neuropathic pain in CB1 knockout mice. Neuropharmacology 2006; 50:111-22.
8. Cruz APM, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 1994; 49:171-6.
9. De Andrés J, Pérez-Cajaraville J, Lopez-Alarcón MD, López-Millán JM, Margarit C, Rodrigo-Royo MD, Franco-Gay ML, Abejón D, Ruiz MA, López-Gomez V, Pérez M. Cultural adaptation and validation of the PainDETECT scale into Spanish. Clin J Pain 2012; 28:243-53.
10. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, Kidd B, Bevan S, Winter J. Pain related behaviour in two models of osteoarthritis in the rat knee. PAIN 2004; 112:83-93.
11. Ferretjans R, de Campos SM, Ribeiro-Santos R, Guimaraes FC, de Oliveira K, Cardoso ACA, AraujoMS, Teixeira-Carvalho A, Martins-FilhoOA, Teixeira AL, Salgado JV. Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. Schizophr Res 2014; 156:254-60.
12. Gao X, Wang W, Wei S, Li W. Review of pharmacological effects of Glycyrrhiza radix and its bioactive compounds. Phytotherapy 2009; 34: 2695-700.
13. García-Gutiérrez MS, García-Bueno B, Zoppi S, Leza JC, Manzanares J. Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors. Br J Pharmacol 2012; 165:951-64.
14. García-Gutiérrez MS, Pérez-Ortiz JM, Gutiérrez-Adán A, Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 2010; 160:1773-84.
15. Goldenberg DL. The interface of pain and mood disturbances in the rheumatic diseases. Semin Arthritis Rheum 2010; 40:15-31.
16. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002; 16:1395-8.
17. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-83.
18. Hill MN, Hillard CJ, McEwen BS. Alterations in corticolimbic dendritic morphology and emotional behavior in cannabinoid CB1 receptordeficient mice parallel the effects of chronic stress. Cereb Cortex 2011; 21:2056-64.
19. HillMN, McLaughlin RJ, Bingham B, Shrestha L, Lee TTY, Gray JM, HillardCJ, Gorzalka BB, Viau V. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A 2010; 107:9406-11.
20. Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, Gorzalka BB. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-Adrenal axis. Neuropsychopharmacology 2009; 34:2733-45.
21. Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TTY, Karatsoreos IN, Mackie K, Viau V, Pickel VM, McEwen BS, Liu Q, Gorzalka BB, Hillard CJ. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 2011; 31:10506-15.
22. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-Acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009; 34:1257-62.
23. Hill MN, Miller GE, Ho WSV, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008; 41:48-53.
24. Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS. Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 2010; 30: 14980-6.
25. Huskisson EC. Measurement of pain. Lancet 1974; 2:1127-31.
26. Jaferi A, Bhatnagar S. Corticotropin-releasing hormone receptors in the medial prefrontal cortex regulate hypothalamic-pituitary-Adrenal activity and anxiety-related behavior regardless of prior stress experience. Brain Res 2007; 1186:212-23.
27. Ji G, Sun H, Fu Y, Li Z, Pais-Vieira M, Galhardo V, Neugebauer V. Cognitive impairment in pain through amygdala-driven prefrontal cortical deactivation. J Neurosci 2010; 30:5451-64.
28. Karp JF, Reynolds CF, Butters MA, Dew MA, Mazumdar S, Begley AE, Lenze E, Weiner DK. The relationship between pain and mental flexibility in older adult pain clinic patients. Pain Med 2006; 7:444-52.
29. Kellgren JH, Lawrence JS. Radiological assessment of osteo-Arthrosis. Ann Rheum Dis 1957; 16:494-502.
30. Khoromi S, Muniyappa R, Nackers L, Gray N, Baldwin H, Wong KA, Matheny LA, Moquin B, Rainer A, Hill S, Remaley A, Johnson LL, Max MB, Blackman MR. Effects of chronic osteoarthritis pain on neuroendocrine function in men. J Clin Endocrinol Metab 2006; 91:4313-8.
31. La Porta C, Bura SA, Aracil-Fernández A, Manzanares J, Maldonado R. Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate. PAIN 2013; 154:160-74.
32. La Porta C, Bura SA, Negrete R, Maldonado R. Involvement of the endocannabinoid system in osteoarthritis pain. Eur J Neurosci 2014; 39: 485-500.
33. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283:401-4.
34. Liu MG, Chen J. Preclinical research on pain comorbidity with affective disorders and cognitive deficits: challenges and perspectives. Prog Neurobiol 2014; 116:13-32.
35. Malcher-Lopes R, Di S, Marcheselli VS, Weng F-J, Stuart CT, Bazan NG, Tasker JG. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 2006; 26:6643-50.
36. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002; 159:379-87.
37. McLaughlin RJ, Hill MN, Gorzalka BB. A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. Neurosci Biobehav Rev 2014; 42:116-31.
38. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013; 64:21-47.
39. Meng QY, Chen XN, Tong DL, Zhou JN. Stress and glucocorticoids regulated corticotropin releasing factor in rat prefrontal cortex. Mol Cell. Endocrinol 2011; 342:54-63.
40. Moreira FA, Wotjak CT. Cannabinoids and anxiety. Curr Top Behav Neurosci 2010; 2:429-50.
41. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research. Prog Neurobiol 2011; 93: 385-404.
42. Mutso AA, Radzicki D, Baliki MN, Huang L, Banisadr G, Centeno MV, Radulovic J, Martina M, Miller RJ, Apkarian AV. Abnormalities in hippocampal functioning with persistent pain. J Neurosci 2012; 32: 5747-56.
43. Onaivi ES, Ishiguro H, Gu S, Liu Q-R. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 2012; 26:92-103.
44. PalomoR, Casals-CollM, Sánchez-BenavidesG, QuintanaM, ManeroRM, Rognoni T, Calvo L, Aranciva F, Tamayo F, Peña-Casanova J. Spanish normative studies in young adults (NEURONORMA young adults project): norms for the Rey-Osterrieth Complex Figure (copy and memory) and Free and Cued Selective Reminding Test. Neurologia 2013; 28:226-35.
45. PertweeRG, HowlettAC, AboodME, AlexanderSPH, DiMarzoV, ElphickMR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588-631.
46. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 2009; 12:1152-8.
47. Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies. Semin Arthritis Rheum 2014; 44:531-41.
48. Randall MD. Endocannabinoids and the haematological system. Br J Pharmacol 2007; 152:671-5.
49. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008; 10:R43.
50. Sagar DR, Staniaszek LE, Okine BN, Woodhams S, Norris LM, Pearson RG, GarleMJ, AlexanderSPH, BennettAJ, BarrettDA, KendallDA, Scammell BE, Chapman V. Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 2010; 62:3666-76.
51. Tasker JG, Herman JP. Mechanisms of rapid glucocorticoid feedback inhibition of the hypothalamic-pituitary-Adrenal axis. Stress 2011; 14: 398-406.
52. Ulrich-Lai YM, XieW, Meij JTA, Dolgas CM, Yu L, Herman JP. Limbic and HPA axis function in an animal model of chronic neuropathic pain. Physiol Behav 2006; 88:67-76.
53. van der Kraan PM, Vitters EL, van de Putte LB, van den Berg WB. Development of osteoarthritic lesions in mice by metabolic and mechanical alterations in the knee joints. Am J Pathol 1989; 135: 1001-14.
54. Vera G, Cabezos PA, Martín MI, Abalo R. Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy. Pharmacol Biochem Behav 2013; 105: 205-12.
55. VilagutG, FerrerM, Rajmil L, Rebollo P, Permanyer-MiraldaG, Quintana JM, Santed R, Valderas JM, Ribera A, Domingo-Salvany A, Alonso J. The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments [in Spanish]. Gac Sanit 2005; 19:135-50.
56. Wamsteeker JI, Kuzmiski JB, Bains JS. Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. J Neurosci 2010; 30:11188-96.
57. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67:361-70.